Consistent with the results from clinical pharmacology studies, results from a preplanned meta-analysis of pooled patient-level data from 7 phase 3 prospective, randomized clinical trials comparing IDeg to IGlar in patients with bothT1DM and T2DM showed that treatment with IDeg resulted in significantly lower rates of overall confirmed hypoglycemia in patients with T2DM and significantly lower rates of nocturnal confirmed hypoglycemia in patients with both T1DM and T2DM, as compared with treatment with IGlar.